Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP(2) Receptor Antagonist for Treatment of Asthma

[Image: see text] Further optimization of an initial DP(2) receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compound 11, NVP-QAW039, fevipiprant), whi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Med Chem Lett
Main Authors: Sandham, David A., Barker, Lucy, Brown, Lyndon, Brown, Zarin, Budd, David, Charlton, Steven J., Chatterjee, Devnandan, Cox, Brian, Dubois, Gerald, Duggan, Nicholas, Hall, Edward, Hatto, Julia, Maas, Janet, Manini, Jodie, Profit, Rachael, Riddy, Darren, Ritchie, Catherine, Sohal, Bindi, Shaw, Duncan, Stringer, Rowan, Sykes, David A., Thomas, Matthew, Turner, Katharine L., Watson, Simon J., West, Ryan, Willard, Elisabeth, Williams, Gareth, Willis, Jennifer
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2017
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5430394/
https://ncbi.nlm.nih.gov/pubmed/28523115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.7b00157
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados